Arbutus Biopharma Corp (NASDAQ: ABUS) established initial surge of 6.85% at $3.59, before settling in for the price of $3.36 at the close. Taking a more long-term approach, ABUS posted a 52-week range of $2.30-$4.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 68.89%. Meanwhile, its Annual Earning per share during the time was 18.41%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 11.82%. This publicly-traded company’s shares outstanding now amounts to $189.44 million, simultaneously with a float of $147.38 million. The organization now has a market capitalization sitting at $680.27 million. At the time of writing, stock’s 50-day Moving Average stood at $3.38, while the 200-day Moving Average is $3.53.
Arbutus Biopharma Corp (ABUS) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Arbutus Biopharma Corp industry. Arbutus Biopharma Corp’s current insider ownership accounts for 22.22%, in contrast to 54.16% institutional ownership. According to the most recent insider trade that took place on Feb 04 ’25, this organization’s Chief Financial Officer sold 22,183 shares at the rate of 3.28, making the entire transaction reach 72,827 in total value, affecting insider ownership by 159,724. Preceding that transaction, on Feb 04 ’25, Company’s Chief Medical Officer sold 19,348 for 3.28, making the whole transaction’s value amount to 63,519. This particular insider is now the holder of 106,194 in total.
Arbutus Biopharma Corp (ABUS) Earnings and Revenue Records
Arbutus Biopharma Corp’s EPS increase for this current 12-month fiscal period is 11.82% and is forecasted to reach -0.33 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 2.33% through the next 5 years, which can be compared against the 18.41% growth it accomplished over the previous five years trading on the market.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
Let’s observe the current performance indicators for Arbutus Biopharma Corp (ABUS). It’s Quick Ratio in the last reported quarter now stands at 7.02. The Stock has managed to achieve an average true range (ATR) of 0.14. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 100.93.
In the same vein, ABUS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.43, a figure that is expected to reach -0.08 in the next quarter, and analysts are predicting that it will be -0.33 at the market close of one year from today.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
Now, what If we examine the latest scores posted by [Arbutus Biopharma Corp, ABUS]. During the last 5-days, its volume was lower the volume of 0.73 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 68.92% While, its Average True Range was 0.14.
Raw Stochastic average of Arbutus Biopharma Corp (ABUS) in the period of the previous 100 days is set at 32.11%, which indicates a major fall in contrast to 97.73% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 39.45% that was lower than 41.55% volatility it exhibited in the past 100-days period.
